JPM24: Amgen CEO hopes to take a bite of competitive obesity market with unique approach

After last year saw the rise of popular obesity treatments, biopharma's interest in the field only appears to only be growing. As established players Novo Nordisk and Eli Lilly look to extend their foothold in the disease area, several competitors wait on the sidelines, eager to enter the ring.

For its part, Amgen didn’t “wake up one day and say gosh, there’s a big market for obesity medicines, maybe we ought to jump in,” CEO Robert Bradway remarked at the 42nd annual J.P. Morgan Healthcare Conference in San Francisco. Instead, the company has been eying the disease area over time and looking to “thoughtfully" make a play.